Die Pharmakokinetik von 5-Fluorouracil und seine Permeation in Pleuraergüsse bei der Therapie des metastasierenden Mamma-Karzinoms

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Bei 9 Patientinnen mit Mamma-Karzinom und Pleurakarzinosen, die im Rahmen des CMF-Schema 600 mg/m2 5-Fluorouracil i.v. erhielten, wurde die Pharmakokinetik von 5-Fluorouracil und seine Permeation in maligne Ergüsse untersucht. Trotz der kurzen Plasmahalbwertzeit von 5-Fluorouracil (16,8 min) konnten in den Ergüssen deutliche Wirkspiegel mit Gipfelkonzentrationen bis 115 nmol/ml nach 30 Minuten beobachtet werden. Infolge der raschen Elimination von 5-Fluorouracil im Plasma und der vergleichsweise langsamen Rückdiffusion aus dem Pleuraraum (t1/2 55 min) persistierten die Spiegel in den Ergüssen wesentlich länger als im Blut. Die Fläche unter der Pleuraspiegelkurve (AUC) erreichte 50% (27–85%) der entsprechenden Plasmawerte (AUC 10,9 ± 2,3 μmol × min × ml-1). Unter systemischer Therapie eines Mamma-Karzinoms mit malignen Pleuraergüssen sind daher aus pharmakokinetischer Sicht keine zusätzlichen lokalen 5-Fluorouracil-Instillationen erforderlich.

Related collections

Author and article information

Journal

Journal ID (publisher-id): ONK

Journal ID (nlm-ta): Oncol Res Treat

Journal ID (doi): 10.1159/issn.2296-5270

Title: Oncology Research and Treatment

Publisher: S. Karger AG

ISSN (Print): 2296-5270

ISSN (Electronic): 2296-5262

Publication date Subscription-year: 1984

Publication date (Print): 1984

Publication date (Electronic): 21 April 2009

Volume: 7

Issue: 1

Pages: 22-26

Affiliations

Poliklinik für Innere Medizin der Medizinischen Hochschule Lübeck

Article

Publisher ID: 215395 Other ID: Onkologie 1984;7:22–26

DOI: 10.1159/000215395

PubMed ID: 6369203

SO-VID: 6eacf4d4-30ab-473f-ad7a-cfc226e35b07

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Page count

Pages: 5

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Call for Papers: Cancer Biology and Therapy

Submit here by August 31, 2025